CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are
promising cancer therapeutic targets. Herein, we report the discovery of highly potent …

CBP/p300 proteins are key epigenetic regulators and promising targets for the treatment of
castration-resistant prostate cancer and other types of human cancers. Herein, we report the …

The histone acetyltransferase CREB-binding protein (CBP) and its paralogue p300 protein
are key transcriptional coactivators and attractive cancer therapeutic targets. We describe …

Bicalutamide resistant LNCaP tumour bearing athymic nude mice were treated with
Enzalutamide by oral gavage, once daily (4mg/kg), or CCS1477 by oral gavage, once daily …

In advanced prostate cancer, CREB (cAMP-responsive element-binding protein) binding
protein (CBP) and its homolog EP300 are highly expressed; targeting the bromodomain of …

The transcriptional coactivator cAMP response element binding protein (CREB)-binding
protein (CBP) and its homologue p300 have emerged as attractive therapeutic targets for …

Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed
prostate cancers, but effective treatments for castration-resistant disease remain elusive …

Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer
(CRPC) is associated with sustained AR signaling, including through alternative splicing of …

Adenoviral E1A binding protein 300 kDa (p300) and its closely related paralog CREB
binding protein (CBP) are promising therapeutic targets for human cancer. Here, we report …

Simple Summary The CREB-binding protein (CBP) and p300 are paralogous lysine
acetyltransferases that serve as critical co-activators for transcription factors involved in …